On the Road to ROME: Defining Tissue-Liquid Concordance in Precision Oncology.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 41148201.
- Also identified by DOI 10.1158/1078-0432.CCR-25-3143.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A growing body of evidence has established liquid biopsy as a promising, noninvasive platform for genomic profiling. In this commentary, we build on findings from the multicenter, randomized phase II ROME trial and interrogate the challenges and opportunities of tissue-liquid profiling concordance in improving personalized cancer treatment and survival outcomes. See related article by Botticelli et al., p. 45.
Medical subject headings
- Precision Medicine
- Neoplasms
- Biomarkers, Tumor